These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36269298)

  • 21. Bimekizumab for the Treatment of Psoriasis.
    Freitas E; Blauvelt A; Torres T
    Drugs; 2021 Oct; 81(15):1751-1762. PubMed ID: 34623614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
    N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
    Blauvelt A; Papp KA; Merola JF; Gottlieb AB; Cross N; Madden C; Wang M; Cioffi C; Griffiths CEM
    J Am Acad Dermatol; 2020 Nov; 83(5):1367-1374. PubMed ID: 32473974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ixekizumab treatment for drug-induced erythrodermic psoriasis.
    Pinto-Pulido EL; Polo-Rodríguez I; González-Cañete M; García-Verdú E; Piteiro-Bermejo AB; Medina-Montalvo S
    Dermatol Ther; 2022 Nov; 35(11):e15863. PubMed ID: 36175131
    [No Abstract]   [Full Text] [Related]  

  • 26. Bimekizumab for the treatment of psoriatic disease.
    Natsis NE; Gottlieb AB
    Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.
    Lo Y; Tsai TF
    Br J Dermatol; 2019 Nov; 181(5):1106-1107. PubMed ID: 31145806
    [No Abstract]   [Full Text] [Related]  

  • 28. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
    Gordon KB; Langley RG; Warren RB; Okubo Y; Stein Gold L; Merola JF; Peterson L; Wixted K; Cross N; Deherder D; Thaçi D
    JAMA Dermatol; 2022 Jul; 158(7):735-744. PubMed ID: 35544084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of erythrodermic psoriasis successfully treated with ixekizumab.
    Megna M; Gallo L; Balato N; Balato A
    Dermatol Ther; 2019 Mar; 32(2):e12825. PubMed ID: 30650216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine-induced erythrodermic psoriasis in a child successfully treated with secukinumab: A case report and brief literature review.
    Zhao Z; Zhang X; Wang R; Wang Y; Gong L; Li C
    Dermatol Ther; 2022 Sep; 35(9):e15684. PubMed ID: 35789520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The next quantum leap forward? Bimekizumab for psoriasis.
    Huang WW; Feldman SR
    Lancet; 2021 Feb; 397(10273):446-448. PubMed ID: 33549176
    [No Abstract]   [Full Text] [Related]  

  • 32. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
    Oliver R; Krueger JG; Glatt S; Vajjah P; Mistry C; Page M; Edwards H; Garcet S; Li X; Dizier B; Maroof A; Watling M; El Baghdady A; Baeten D; Ionescu L; Shaw S
    Br J Dermatol; 2022 Apr; 186(4):652-663. PubMed ID: 34687214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.
    Rongioletti F; Borenstein M; Kirsner R; Kerdel F
    J Dermatolog Treat; 2003 Dec; 14(4):222-5. PubMed ID: 14660268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Griffith SK; Ahn GS; Wu JJ
    N Engl J Med; 2021 Sep; 385(12):1149-1150. PubMed ID: 34525293
    [No Abstract]   [Full Text] [Related]  

  • 35. Bimekizumab versus Adalimumab in Plaque Psoriasis. Reply.
    Warren RB; Cioffi C; Peterson L
    N Engl J Med; 2021 Sep; 385(12):1150. PubMed ID: 34525294
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
    Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of bimekizumab over 3 years in patients with psoriasis.
    Br J Dermatol; 2024 Mar; 190(4):e38. PubMed ID: 38488653
    [No Abstract]   [Full Text] [Related]  

  • 38. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
    Reis J; Vender R; Torres T
    BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report.
    Lu J; Tang S; Yu N; Yi X; Li Y
    J Int Med Res; 2020 Nov; 48(11):300060520969494. PubMed ID: 33161790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of recalcitrant erythrodermic psoriasis with ustekinumab.
    Stinco G; Piccirillo A; Errichetti E; Bergamo S; Patrone P
    Eur J Dermatol; 2014; 24(3):387-90. PubMed ID: 24721883
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.